Targeting protein clearance mechanisms

Studies of human genetics indicate that impairment of protein clearance mechanisms is likely the most common cause of familial (genetic) forms of Parkinson’s disease and other neurodegenerative diseases (12, 13, 14). Studies in animal models further suggest that these impaired protein clearance mechanisms (called autophagy- Greek: 'self-eating' = self-clearance) may contribute to both genetic and non-genetic forms of the disorder (15, 16, 17, 18).

Neuropore Therapies has several programs that target specific mechanisms in autophagy, particularly, macroautophagy that is responsible for clearance of large misfolded protein aggregates as well as dysfunctional cellular organelles. (see 19-20 for reviews) As part of this effort we have developed a number of novel approaches to measuring the function of autophagy pathways in vitro and in animal models. We have also identified novel molecules that are now being evaluated as therapeutic candidates, and which could enter clinical development in 2016.